Literature DB >> 27988512

Urine Epidermal Growth Factor, Monocyte Chemoattractant Protein-1 or Their Ratio as Biomarkers for Interstitial Fibrosis and Tubular Atrophy in Primary Glomerulonephritis.

Supanat Worawichawong1, Suchin Worawichawong, Piyanuch Radinahamed, Dittapol Muntham, Nuankanya Sathirapongsasuti, Arkom Nongnuch, Montira Assanatham, Chagriya Kitiyakara.   

Abstract

BACKGROUND/AIMS: The degree of tubular atrophy and interstitial fibrosis (IFTA) is an important prognostic factor in glomerulonephritis. Imbalance between pro-inflammatory cytokines such as monocyte chemoattractant protein- 1 (MCP-1) and protective cytokines such as epidermal growth factor (EGF) likely determine IFTA severity. In separate studies, elevated MCP-1 and decreased EGF have been shown to be associated with IFTA severity. In this study, we aim to evaluate the predictive value of urinary EGF/MCP-1 ratio compared to each biomarker individually for moderate to severe IFTA in primary glomerulonephritis (GN).
METHODS: Urine samples were collected at biopsy from primary GN (IgA nephropathy, focal and segmental glomerulosclerosis, minimal change disease, membranous nephropathy). MCP-1 and EGF were analyzed by enzyme-linked immunosorbent assay.
RESULTS: EGF, MCP-1 and EGF/MCP-1 ratio from primary GN, all correlated with IFTA (n=58). By univariate analysis, glomerular filtration rate, EGF, and EGF/MCP-1 ratio were associated with IFTA. By multivariate analysis, only EGF/MCP-1 ratio was independently associated with IFTA. EGF/MCP-1 ratio had a sensitivity of 88% and specificity of 74 % for IFTA. EGF/MCP-1 had good discrimination for IFTA (AUC=0.85), but the improvement over EGF alone was not significant.
CONCLUSION: EGF/MCP-1 ratio is independently associated IFTA severity in primary glomerulonephritis, but the ability of EGF/MCP-1 ratio to discriminate moderate to severe IFTA may not be much better than EGF alone.
© 2016 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27988512     DOI: 10.1159/000452595

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  10 in total

1.  The Relationship of Residual Renal Function with Cardiovascular Morbidity in Hemodialysis Patients and the Potential Role of Monocyte Chemoattractant Protein-1.

Authors:  Vaia D Raikou; Vasilios Kardalinos; Despina Kyriaki
Journal:  Kidney Dis (Basel)       Date:  2017-11-17

2.  Novel Mechanism of the Pericyte-Myofibroblast Transition in Renal Interstitial Fibrosis: Core Fucosylation Regulation.

Authors:  Nan Wang; Yiyao Deng; Anqi Liu; Nan Shen; Weidong Wang; Xiangning Du; Qingzhu Tang; Shuangxin Li; Zach Odeh; Taihua Wu; Hongli Lin
Journal:  Sci Rep       Date:  2017-12-05       Impact factor: 4.379

Review 3.  Tubulointerstitial Biomarkers for Diabetic Nephropathy.

Authors:  Bancha Satirapoj
Journal:  J Diabetes Res       Date:  2018-02-08       Impact factor: 4.011

4.  Renal expression of trefoil factor 3 mRNA in association with tubulointerstitial fibrosis in IgA nephropathy.

Authors:  Keiko Tanaka; Hitoshi Sugiyama; Toshio Yamanari; Koki Mise; Hiroshi Morinaga; Masashi Kitagawa; Akifumi Onishi; Ayu Ogawa-Akiyama; Katsuyuki Tanabe; Jun Eguchi; Yasukazu Ohmoto; Kenichi Shikata; Jun Wada
Journal:  Nephrology (Carlton)       Date:  2018-07-26       Impact factor: 2.506

5.  Urinary Epidermal Growth Factor/Creatinine Ratio and Graft Failure in Renal Transplant Recipients: A Prospective Cohort Study.

Authors:  Manuela Yepes-Calderón; Camilo G Sotomayor; Matthias Kretzler; Rijk O B Gans; Stefan P Berger; Gerjan J Navis; Wenjun Ju; Stephan J L Bakker
Journal:  J Clin Med       Date:  2019-10-13       Impact factor: 4.241

6.  C5a receptor inhibitor avacopan in immunoglobulin A nephropathy-an open-label pilot study.

Authors:  Annette Bruchfeld; Hasan Magin; Patrick Nachman; Samir Parikh; Richard Lafayette; Antonia Potarca; Shichang Miao; Pirow Bekker
Journal:  Clin Kidney J       Date:  2022-01-24

7.  Urinary EGF and MCP-1 and risk of CKD after cardiac surgery.

Authors:  Steven Menez; Wenjun Ju; Rajasree Menon; Dennis G Moledina; Heather Thiessen Philbrook; Eric McArthur; Yaqi Jia; Wassim Obeid; Sherry G Mansour; Jay L Koyner; Michael G Shlipak; Steven G Coca; Amit X Garg; Andrew S Bomback; John A Kellum; Matthias Kretzler; Chirag R Parikh
Journal:  JCI Insight       Date:  2021-06-08

8.  Urinary epidermal growth factor, monocyte chemoattractant protein-1 or their ratio as predictors for rapid loss of renal function in type 2 diabetic patients with diabetic kidney disease.

Authors:  Bancha Satirapoj; Rattanawan Dispan; Piyanuch Radinahamed; Chagriya Kitiyakara
Journal:  BMC Nephrol       Date:  2018-09-21       Impact factor: 2.388

9.  Predicting treatment response and clinicopathological findings in lupus nephritis with urine epidermal growth factor, monocyte chemoattractant protein-1 or their ratios.

Authors:  Pintip Ngamjanyaporn; Suchin Worawichawong; Prapaporn Pisitkun; Khantong Khiewngam; Surasak Kantachuvesiri; Arkom Nongnuch; Montira Assanatham; Nuankanya Sathirapongsasuti; Chagriya Kitiyakara
Journal:  PLoS One       Date:  2022-03-10       Impact factor: 3.240

10.  Epidermal Growth Factor Protects Against High Glucose-Induced Podocyte Injury Possibly via Modulation of Autophagy and PI3K/AKT/mTOR Signaling Pathway Through DNA Methylation.

Authors:  Yan Sun; Ming Deng; Xiao Ke; Xiangyang Lei; Hao Ju; Zhiming Liu; Xiaosu Bai
Journal:  Diabetes Metab Syndr Obes       Date:  2021-05-19       Impact factor: 3.168

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.